Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours

British Journal of Cancer

Volumn 105, Issue 8, 2011, Pages 1173-1175

  Korse, C M ^a   Muller, M ^a   Taal, B G ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

chromogranin A; H2 receptor antagonists; neuroendocrine tumours; proton pump inhibitors

Indexed keywords

CHROMOGRANIN A; OMEPRAZOLE; RANITIDINE;

ADULT; AGED; ARTICLE; DISEASE COURSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHROMOGRANIN A; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PROTON PUMP INHIBITORS; YOUNG ADULT;

EID: 80054007991     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.380     Document Type: Article

References (12)

1. Degorce F, Goumon Y, Jacquemart L, Vidaud C, Bellanger L, Pons-Anicet D, Seguin P, Metz-Boutigue MH, Aunis D (1999) A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145-245). Br J Cancer 79: 65-71 (Pubitemid 28566928)
2. Desta Z, Zhao X, Shin JG, Flockhart DA (2002) Clinical significance of the cyto-chrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41: 913-958 (Pubitemid 35168437)
3. Dittadi R, Meo S, Gion M (2004) Biological variation of plasma chromogranin A. Clin Chem Lab Med 42: 109-110
4. Driman DK, Wright C, Tougas G, Riddell RH (1996) Omeprazole produces parietal cell hypertrophy and hyperplasia in humans. Dig Dis Sci 41: 2039-2047 (Pubitemid 26366806)
5. Giusti M, Sidoti M, Augeri C, Rabitti C, Minuto F (2004) Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol 150: 299-303 (Pubitemid 38443779)
6. Korse CM, Bonfrer JM, Aaronson NK, Hart AA, Taal BG (2009) Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendo-crine tumors. Neuroendocrinology 89: 296-301
7. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M (2010) Chromogranin a-biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 17: 2427-2443
8. O'Toole D, Grossman A, Gross D, Delle Fave G, Barkmanova J, O0Connor J, Pape UF, Plockinger U (2009) ENETS Consensus guidelines for the standards of care in neuroendocrine tumors: biochemical markers. Neuroendocrinology 90: 194-202
9. Sanduleanu S, Stridsberg M, Jonkers D, Hameeteman W, Biemond I, Lundqvist G, Lamers C, Stockbrugger RW (1999) Serum gastrin and chromogranin A during medium-and long-term acid suppressive therapy: a case-control study. Aliment Pharmacol Ther 13: 145-153 (Pubitemid 29090008)
10. Tramonti G, Ferdeghini M, Annichiarico C, Norpoth M, Donadio C, Bianchi R, Bianchi C (2001) Relationship between renal function and blood level of chromogranin A. Ren Fail 23: 449-457 (Pubitemid 32692280)
11. Vezzosi D, Walter T, Laplanche A, Raoul JL, Dromain C, Ruszniewski P, d0Herbomez M, Guigay J, Mitry E, Cadiot G, Leboulleux S, Lombard-Bohas C, Borson-Chazot F, Ducreux M, Baudin E (2011) Chromogranin A measurement in metastatic well-differentiated gastroenteropancreatic neuroendocrine carcinoma: screening for false positives and a prospective follow-up study. Int J Biol Markers 26: 94-101
12. Waldum HL, Arnestad JS, Brenna E, Eide I, Syversen U, Sandvik AK (1996) Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 39: 649-653 (Pubitemid 26426463)